Avatrombopag indications

Avatrombopagis a platelet-raising drug indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo surgery and for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia(ITP) who have had an inadequate response to prior therapy.

Avatrombopagis an orally bioavailable small moleculeTPO receptor agonist that stimulates megakaryocyte proliferation and differentiation of bone marrow progenitor cells, leading to increased platelet production. Avatrombopagdoes not compete with TPO for binding to TPO receptors, and has additive effects with TPO on platelet production. Administration of DOPTELET to adult patients may result in dose- and dose-dependent increases in platelet counts. An initial increase in platelet count was observed within 3 to 5 days after starting treatment, reaching a peak value 10 to 13 days later. After treatment, platelet counts gradually decreased and returned to values u200bu200bclose to baseline.

Avatrombopag T is available as immediate-release tablets. Each DOPTELET tablet contains 20 mg avatrombopag (equivalent to 23.6mg AvatrombopagMaleate)and the following inactive ingredients:Lactose monohydrate, colloidal silicon dioxide, crospovidone, magnesium stearate, and microcrystalline cellulose. Coating film:Polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide, iron oxide yellow. AvatrombopagThe chemical name of the maleate salt is 4-piperidinecarboxylic acid, 1-[3-chloro-5-[[4-(4-chloro-2-thienyl )-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-Pyridyl]-, (2Z)-2-Butenedioate(1:1). Its molecular formula isC29H34Chlorine2N6O3S2C4H4O4. The molecular weight is 765.73.

The imitation version costs about 600 to 900 per box, and a box contains 28 tablets. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.